Omeros (NASDAQ:OMER) Lowered to Sell Rating by Wall Street Zen

Omeros (NASDAQ:OMER - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Friday.

A number of other equities research analysts also recently weighed in on the company. D. Boral Capital reaffirmed a "buy" rating and set a $36.00 price objective on shares of Omeros in a report on Tuesday, May 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a report on Friday, May 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Omeros currently has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Stock Performance

NASDAQ OMER traded up $0.47 during trading on Friday, reaching $3.77. 1,040,299 shares of the company traded hands, compared to its average volume of 681,964. The stock's 50 day moving average price is $5.45 and its two-hundred day moving average price is $7.94. The company has a market cap of $220.90 million, a price-to-earnings ratio of -1.63 and a beta of 2.20. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). Equities research analysts expect that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. acquired a new position in shares of Omeros in the 4th quarter worth approximately $124,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Omeros by 12.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company's stock worth $392,000 after acquiring an additional 4,401 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Omeros in the 4th quarter worth approximately $46,000. Cerity Partners LLC boosted its holdings in shares of Omeros by 9.9% in the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 2,600 shares in the last quarter. Finally, Deutsche Bank AG boosted its holdings in shares of Omeros by 38.2% in the 4th quarter. Deutsche Bank AG now owns 40,046 shares of the biopharmaceutical company's stock worth $396,000 after acquiring an additional 11,068 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.